Advances in The Understanding and Management of Obsessive-Compulsive Disorder: A Comprehensive Review

Abstract

Obsessive-Compulsive Disorder (OCD) is a chronic and disabling psychiatric condition characterized by intrusive obsessions and repetitive compulsions, which significantly impair daily functioning. This review provides a comprehensive overview of the etiology, epidemiology, pathophysiology, diagnostic criteria, clinical features, and evaluation methods associated with OCD. The disorder involves a complex interplay of genetic, neurobiological, and environmental factors, with dysregulation in the cortico-striato-thalamo-cortical circuitry playing a pivotal role. Cognitive-Behavioral Therapy (CBT), particularly Exposure and Response Prevention (ERP), and pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs) remain the first-line treatments. For refractory cases, neuromodulation techniques such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) offer promising outcomes. Recent advances in neuroimaging, genetics, epigenetics, and digital therapeutic platforms are transforming the landscape of OCD diagnosis and treatment. The integration of precision psychiatry and novel pharmacological agents targeting glutamatergic pathways represents the future direction in personalized OCD management.

Keywords

Obsessive-Compulsive Disorder, CBT, SSRI, Neurobiology, ERP, Neuromodulation, Deep Brain Stimulation, Transcranial Magnetic Stimulation, Glutamate, Precision Psychiatry, PANDAS, Genetic Studies, Digital CBT

Introduction

Etiology:

OCD's etiology is diverse, including cognitive, genetic, physiological, environmental, and neurological components. [4]

1. Genetics: Having a relative with OCD raises the risk of developing it. However, not everyone with a genetic variation gets OCD, and not everyone with OCD has a genetic variation.
2. Brain differences: Individuals with OCD may have changes in frontal cortex and subcortical areas that regulate behaviour and emotions.
3. Neurotransmitter: OCD may be associated with alterations in the brain's reaction to neurotransmitters such as serotonin or dopamine.
4. Personality: Anxiety, high personal standards, and attention to detail may increase the risk of developing OCD. [5]

Epidemiology:

Obsessive-compulsive disorder is the largest cause of psychiatric morbidity worldwide, affecting 1% to 3% of the population. OCD is commonly accompanied with other psychiatric Obsessive disorders. OCD typically manifests early in life and has a long-term etiology. The most commonly affected demographic range is 18 to 29 years old. Surprisingly, one-quarter of adult males exhibit symptoms before the age of ten, although females typically develop the disease during childhood. Furthermore, the perimetrium and postpartum stages have been identified as high-risk periods for women, with greater rates of OCD development than in nonpregnant women. Women are approximately 1.6 times as likely than men to be tortured by the condition. Approximately 90% of OCD sufferers meet the criteria for at least one other psychiatric disorder. [1]

Pathophysiology:

While OCD is generally thought to be caused by a combination of circumstances, some cases can be specifically related to neurological causes involving the basal ganglia. [6] The current model for the pathophysiology of OCD is complicated. Neuroimaging studies reveal involvement of the dorsolateral prefrontal cortex, basal ganglia, and thalamus. [7] The response to selective serotonin reuptake inhibitors (SSRIs) suggests that the serotonin system plays a significant role in the neurochemistry of OCD. Family studies have revealed that genetics have a role in the etiology of OCD, particularly in its early-onset variant. [8] An immunologic component has also been proposed, based on the association between OCD and paediatric autoimmune neuropsychiatric illness associated with streptococcal infections (PANDAS), a condition in which children develop OCD symptoms or tics after contracting group A Streptococcus. [9]

Risk Factor of Ocd:

1. Family history: Having parents or other family members with the illness can increase your chances of developing OCD.
2. Life events: If you have experienced traumatic or stressful experiences, your risk may increase. This reaction may result in intrusive thoughts, rituals, and mental suffering associated with OCD.
3. Other mental health diseases: OCD may be associated with other mental health illnesses, such as anxiety, depression, substance misuse, or tic disorders. [10]

Obsessive- Compulsive Disorder Diagnostic Area:

The presence of obsession, compulsion or both:

• Obsessive thoughts, urges, or visions that occur during a disturbance might induce anxiety and   distress.

• Compulsion refers to repetitive behaviours or mental acts driven by obsession or strict regulations

Clinical Assesment:

Obsessions with cleanliness and cleaning might lead to contamination.

• Compulsive checking and fear of inflicting harm are examples of harmful ideas.
• Obsessions with forbidden notions, such as aggression, sexuality, or religion, can indicate a poor prognosis.
• Symmetry: compulsions such as repeating, sorting, and counting [11].

Evaluation:

Screening for the right symptoms of OCD is crucial. The short OCD screener is a frequently used tool. This six-question screening procedure, with a 97% sensitivity, is a simple and effective tool to identify patients with OCD symptoms. [12]

• Time occupied by obsessive thoughts and compulsions
• Interference of obsessive thoughts
• Distress of obsessive thoughts
• Resistance against obsessions
• Degree of control over obsessive thoughts
• Time occupied by compulsive behavior
• Interference of compulsive behavior
• Distress associated with compulsive behavior
• Resistance against compulsive behavior
• Degree of control over compulsive behaviors [13]

Management Of OCD:

1. Psychotherapy:

Cognitive-behavioral therapy (CBT) is an empirically supported psychotherapy strategy for OCD. [14] Within the context of CBT, exposure and response prevention (ERP) stands out as the most empirically supported behavioral technique. ERP comprises exposing patients to anxiety-provoking stimuli while directing them to avoid following compulsive behaviours. [15] Individual and group therapy, as well as in-person and internet-based approaches, have all been beneficial in treating OCD. [16] Adherence to at-home assignments, particularly home-based ERP exercises, is an important driver of therapy efficacy. CBT is a first-line treatment for OCD, particularly when it matches with the patient's treatment preferences and skilled practitioners are available. Although meta-analyses indicate that CBT generally outperforms pharmaceutical therapies, such results should be approached with caution, taking into account variables such as patient selection criteria and baseline severity of OCD symptoms. [1], [17]

2. Pharmacotherapy:

Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line treatments due to their efficacy, safety, and tolerability. [18] The treatment recommendations prescribe an 8- to 12-week SSRI trial to establish efficacy. However, new meta-analyses demonstrate that SSRI medication produces significant symptom relief within the first two weeks. [19] An open-label fluoxetine study discovered that symptom reduction over four weeks predicted 12-week treatment success. [20] Maintenance treatment is often suggested for at least 12 to 24 months after remission, while longer periods may be required due to the risk of relapse following medication cessation. [21] Clomipramine, a tricyclic antidepressant (TCA), was the first medication to be beneficial in treating OCD. Meta-analyses suggest that it is more effective than SSRIs, although this conclusion should be read cautiously because early clomipramine trials contained fewer treatment-resistant individuals [1]

3. Neuromodulation:

• Transcranial magnetic stimulation: Studies that used repetitive transcranial magnetic stimulation (rTMS) on various brain regions (e.g., the dorsolateral prefrontal cortex [dlPFC], dorsomedial prefrontal cortex [dmPFC], and orbitofrontal cortex [OFC]) produced mixed results. However, these investigations usually support the notion that cortico-striatal hyperactivity is an underlying component in OCD. [22] Deep transcranial magnetic stimulation (dTMS), which uses an H-shaped coil, can reach depths of 3 to 5 cm, focusing on midline areas such the medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC). [23] The US Food and Drug Administration (FDA) approved dTMS for the treatment of OCD. [24]
• Deep brain stimulation: Deep brain stimulation (DBS) is a reversible, modifiable treatment for intractable OCD, with response rates ranging from 40% to 70%. It involves the neurosurgical implantation of an electrode that can activate neighboring neuronal circuits. [25] DBS focusses on the anterior limb of the internal capsule and the ventral striatum. [26]

Recent Trends in Ocd:

• Neurobiological advancement: Neuroimaging: High-resolution MRI and functional connectivity investigations show unique circuit abnormalities in cortico-striato-thalamo-cortical (CSTC)loop.

Biomarkers: Current research is aimed at identifying reliable biomarkers.

 (e.g., inflammatory cytokines, glutamate levels) for diagnosing and treating PM.

• Genetic and epigenetic sight: Genome-wide association studies (GWAS) are uncovering probable genetic variations associated with OCD, such as those in genes connected to the serotonin and glutamate pathways.

Epigenetics: Methylation patterns and environmental influences on gene expression are being investigated.

• Expanding psychotherapeutic approaches: Digital CBT (e-CBT): Online CBT systems and smartphone apps are becoming increasingly popular for accessibility. Inference-based therapy (IBT) is a recent strategy that targets OCD's flawed reasoning and has shown promise in some clinical trials.
• Pharmacologic development: Glutamate-modulating agents: N-acetylcysteine, memantine, and ketamine are being investigated as SSRI replacements or adjuncts. Precision psychiatry: Efforts are ongoing to personalise treatment based on genetic, neurochemical, and cognitive characteristics.
• Neuromodulation Therapies: Transcranial magnetic stimulation (TMS): FDA-approved for OCD. [27].

REFERENCES

1. Stein DJ, Costa DL, Lochner C, Miguel EC, Reddy YJ, Shavitt RG, van den Heuvel OA, Simpson HB. Obsessive–compulsive disorder. Nature reviews Disease primers. 2019 Aug 1;5(1):52.
2. Chen X, Yue J, Luo Y, Huang L, Li B, Wen S. Distinct behavioral traits and associated brain regions in mouse models for obsessive–compulsive disorder. Behavioral and Brain Functions. 2021 May 18;17(1):4.
3. Mataix-Cols D, do Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. American Journal of Psychiatry. 2005 Feb 1;162(2):228-38.
4. Goodman WK, Storch EA, Sheth SA. Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. American Journal of Psychiatry. 2021 Jan 1;178(1):17-29.
5. Jalal B, Chamberlain SR, Sahakian BJ. Obsessive?compulsive disorder: Etiology, neuropathology, and cognitive dysfunction. Brain and behavior. 2023 Jun;13(6):e3000.
6. Fernandez TV, Leckman JF, Pittenger C. Genetic susceptibility in obsessive-compulsive disorder. Handbook of clinical neurology. 2018 Jan 1; 148:767-81.
7. Friedlander L, Desrocher M. Neuroimaging studies of obsessive–compulsive disorder in adults and children. Clinical psychology review. 2006 Jan 1;26(1):32-49.
8. Pauls DL. The genetics of obsessive-compulsive disorder: a review of the evidence. InAmerican journal of medical genetics part C: seminars in medical genetics 2008 May 15 (Vol. 148, No. 2, pp. 133-139). Hoboken: Wiley Subscription Services, Inc., A Wiley Company.
9. Vahia VN. Diagnostic and statistical manual of mental disorders 5: A quick glance. Indian journal of psychiatry. 2013 Jul 1;55(3):220-3.
10. Wang L, Simpson HB, Dulawa SC. Assessing the validity of current mouse genetic models of obsessive–compulsive disorder. Behavioural pharmacology. 2009 Mar 1;20(2):119-33.
11. Pigott TA, L'Heureux F, Dubbert B, Bernstein S, Murphy DL. Obsessive compulsive disorder: comorbid conditions. The Journal of clinical psychiatry. 1994 Oct 1; 55:15-27.
12. Krebs G, Heyman I. Obsessive-compulsive disorder in children and adolescents. Archives of disease in childhood. 2015 May 1;100(5):495-9.
13. Schruers K, Baldi S, van den Heuvel T, Goossens L, Luyten L, Leentjens AF, Ackermans L, Temel Y, Viechtbauer W. The effects of deep-brain non-stimulation in severe obsessive-compulsive disorder: an individual patient data meta-analysis. Translational Psychiatry. 2019 Aug 5;9(1):183.
14.  Öst LG, Havnen A, Hansen B, Kvale G. Cognitive behavioral treatments of obsessive–compulsive disorder. A systematic review and meta-analysis of studies published 1993–2014. Clinical psychology review. 2015 Aug 1; 40:156-69.
15. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. Jama. 2017 Apr 4;317(13):1358-67.
16. Öst LG, Riise EN, Wergeland GJ, Hansen B, Kvale G. Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis. Journal of Anxiety Disorders. 2016 Oct 1; 43:58-69.
17. Kvale G, Hansen B, Björgvinsson T, Børtveit T, Hagen K, Haseth S, Kristensen UB, Launes G, Ressler KJ, Solem S, Strand A. Successfully treating 90 patients with obsessive compulsive disorder in eight days: the Bergen 4-day treatment. BMC psychiatry. 2018 Dec; 18:1-9.
18. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular psychiatry. 2010 Aug;15(8):850-5.
19. Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal of clinical psychiatry. 2016 May 25;77(5):21133.
20. Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2016 Oct 1;55(10):851-9.
21. da Conceição Costa DL, Shavitt RG, Cesar RC, Joaquim MA, Borcato S, Valério C, Miguel EC, Diniz JB. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. Journal of psychiatric research. 2013 Nov 1;47(11):1700-7.
22. Dunlop K, Woodside B, Olmsted M, Colton P, Giacobbe P, Downar J. Reductions in cortico-striatal hyperconnectivity accompany successful treatment of obsessive-compulsive disorder with dorsomedial prefrontal rTMS. Neuropsychopharmacology. 2016 Apr;41(5):1395-403.
23. Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: A prospective multicenter randomized double-blind placebo-controlled trial. Focus. 2022 Jan;20(1):152-9.
24. McCathern AG, Mathai DS, Cho RY, Goodman WK, Storch EA. Deep transcranial magnetic stimulation for obsessive compulsive disorder. Expert review of neurotherapeutics. 2020 Oct 2;20(10):1029-36.
25. Li N, Baldermann JC, Kibleur A, Treu S, Akram H, Elias GJ, Boutet A, Lozano AM, Al-Fatly B, Strange B, Barcia JA. A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder. Nature communications. 2020 Jul 3;11(1):3364.
26. Goodman WK, Storch EA, Sheth SA. Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. American Journal of Psychiatry. 2021 Jan 1;178(1):17-29.
27. Eskandar K. Emerging trends in the treatment of obsessive-compulsive disorder: a literature review. Debates em Psiquiatria. 2024 Aug 22; 14:1-9.